share_log

Tarsus Pharmaceuticals Analyst Ratings

Benzinga ·  Aug 11, 2023 06:25
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
08/11/2023 146.91% HC Wainwright & Co. $50 → $42 Maintains Buy
07/26/2023 193.94% HC Wainwright & Co. $44 → $50 Maintains Buy
07/18/2023 158.67% William Blair → $44 Initiates Coverage On → Outperform
06/26/2023 158.67% HC Wainwright & Co. $40 → $44 Maintains Buy
06/16/2023 146.91% Guggenheim $40 → $42 Maintains Buy
05/18/2023 Guggenheim Initiates Coverage On → Buy
05/08/2023 152.79% Oppenheimer → $43 Reiterates → Outperform
03/15/2023 135.16% HC Wainwright & Co. → $40 Reiterates → Buy
08/01/2022 135.16% Barclays → $40 Initiates Coverage On → Overweight
12/21/2021 135.16% HC Wainwright & Co. → $40 Initiates Coverage On → Buy
11/23/2021 223.34% Oppenheimer → $55 Initiates Coverage On → Outperform
10/08/2021 282.13% Raymond James $50 → $65 Maintains Strong Buy
06/29/2021 193.94% Raymond James $39 → $50 Maintains Strong Buy
11/10/2020 146.91% Ladenburg Thalmann → $42 Initiates Coverage On → Buy
11/10/2020 94% B of A Securities → $33 Initiates Coverage On → Buy
11/10/2020 105.76% Jefferies → $35 Initiates Coverage On → Buy
11/10/2020 129.28% Raymond James → $39 Initiates Coverage On → Strong Buy

What is the target price for Tarsus Pharmaceuticals (TARS)?

The latest price target for Tarsus Pharmaceuticals (NASDAQ: TARS) was reported by HC Wainwright & Co. on August 11, 2023. The analyst firm set a price target for $42.00 expecting TARS to rise to within 12 months (a possible 146.91% upside). 8 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Tarsus Pharmaceuticals (TARS)?

The latest analyst rating for Tarsus Pharmaceuticals (NASDAQ: TARS) was provided by HC Wainwright & Co., and Tarsus Pharmaceuticals maintained their buy rating.

When is the next analyst rating going to be posted or updated for Tarsus Pharmaceuticals (TARS)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tarsus Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tarsus Pharmaceuticals was filed on August 11, 2023 so you should expect the next rating to be made available sometime around August 11, 2024.

Is the Analyst Rating Tarsus Pharmaceuticals (TARS) correct?

While ratings are subjective and will change, the latest Tarsus Pharmaceuticals (TARS) rating was a maintained with a price target of $50.00 to $42.00. The current price Tarsus Pharmaceuticals (TARS) is trading at is $17.01, which is out of the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment